Design Therapeutics (DSGN) vs Olema Pharmaceuticals (OLMA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Design Therapeutics (DSGN) has outperformed Olema Pharmaceuticals (OLMA) over the past year, gaining 80.1% versus a loss of 23.9%. Over five years, DSGN leads with a -18.0% price change compared with -74.1% for OLMA. Design Therapeutics is the larger company by market cap ($731.6 million vs $694.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DSGN | OLMA |
|---|---|---|
| Share price | $11.69 | $7.94 |
| Market cap | $731.58M | $694.73M |
| 1-day change | -2.34% | +0.25% |
| YTD return | +24.63% | -68.24% |
| 1-year return | +80.12% | -23.95% |
| 5-year return | -17.96% | -74.15% |
| EPS (TTM) | $-1.18 | $-2.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.25 | $36.26 |
| 52-week low | $5.28 | $6.65 |
| Distance from 52-week high | -32.23% | -78.10% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +85.71% | +359.70% |
| Average volume | 607.69K | 1.07M |
| Shares outstanding | 62.58M | 87.50M |
| Employees | 55 | 150 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DSGN has outperformed OLMA by 104.1 percentage points over the past year.
About Design Therapeutics
DSGN stock →Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About Olema Pharmaceuticals
OLMA stock →Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 150 employees
DSGN vs OLMA FAQ
Which is bigger, Design Therapeutics or Olema Pharmaceuticals?
Design Therapeutics (DSGN) is larger, with a market capitalization of $731.58M compared with $694.73M for Olema Pharmaceuticals (OLMA).
Which stock has performed better over the past year, DSGN or OLMA?
DSGN returned +80.12% over the past 12 months, compared with -23.95% for OLMA (price return, excluding dividends). Past performance does not predict future results.
Are Design Therapeutics and Olema Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.